SUFFERN, N.Y., Jan. 22, 2025 /PRNewswire/ -- CDx Diagnostics, Inc., developer and provider of the WATS3D solution, today announces a...
DeepScribe to be the first ambient AI partner for Flatiron Health, integrating with their OncoEMR® to automatically document the complexities...
The approved projects, with an overall budget of $15 million, involve innovations in Electronics, Healthcare, Medical Devices, and Quantum Computing...
ARLINGTON, VIRGINIA / ACCESS Newswire / January 22, 2025 / The Centers for Medicare & Medicaid Services (CMS) has announced...
Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment...
Live webcast on Wednesday, January 29th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics...
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC...
Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab EmiratesPOC data generated from...
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The...
CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a...
Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen...
Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers...
Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and...
Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances...
Premier episode available today across all podcast platformsVALENCIA, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming...
Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment...
VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront...
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population...
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor...
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a...